| Bioactivity | NAN-190 hydrobromide is a serotonin receptor 5-HT antagonist. NAN-190 is a selective antagonist of 5-HT1A[1][3]. |
| In Vivo | NAN-190 hydrobromide (0.5 mg/kg, ip) is injected concomitantly with the effective dose of fluoxetine. NAN-190 reverses the catalepsy-improving effect of fluoxetine in 6-OHDA lesioned rats[2]. |
| Name | NAN-190 hydrobromide |
| CAS | 115338-32-4 |
| Formula | C23H28BrN3O3 |
| Molar Mass | 474.39 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Shahane SA, et al. Detection of phospholipidosis induction: a cell-based assay in high-throughput and high-content format. J Biomol Screen. 2014 Jan;19(1):66-76. [2]. Sharifi H, et al. Dose-Dependent Effect of Flouxetine on 6-OHDA-Induced Catalepsy in Male Rats: A Possible Involvement of 5-HT1A Receptors. Adv Pharm Bull. 2013;3(1):203-6. [3]. Citó MC, et al. Antidepressant-like effect of Hoodia gordonii in a forced swimming test in mice: evidence for involvement of the monoaminergic system. Braz J Med Biol Res. 2015 Jan;48(1):57-64. |